Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParakh, Sen
dc.contributor.authorMurphy, Cen
dc.contributor.authorLau, Den
dc.contributor.authorCebon, Jonathan Sen
dc.contributor.authorAndrews, Miles Cen
dc.identifier.citationJournal of Clinical Pharmacy and Therapeutics 2014; 40(1): 121-3en
dc.description.abstractThe management of metastatic melanoma has changed significantly in the past decade with the development of immunotherapies and targeted molecular therapies. Trials of targeted therapies have focused mainly on patients with the most common BRAF V600 mutations, namely V600E/K substitutions, with very little information available on the benefit of targeted therapies on less commonly occurring mutations such as V600R/D and M.We present a 54-year-old man with metastatic melanoma harbouring a rare BRAF V600M mutation, who experienced clinical and radiological response to combined therapy with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib.As our understanding of these therapies evolves and an increasing number of patients have mutational testing performed, there is a clear imperative--as highlighted by this case--to test for rarer mutations and facilitate their inclusion both in everyday practice and in future clinical trials.en
dc.subject.otherBRAF mutationen
dc.subject.othertargeted therapyen
dc.titleResponse to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of clinical pharmacy and therapeuticsen
dc.identifier.affiliationJoint Austin-Ludwig Medical Oncology Unit, Austin Health, Heidelberg, Vic., Australiaen
dc.identifier.affiliationLudwig Institute for Cancer Research - Austin Branch, Heidelberg, Vic., Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.